Rheumatoid arthritis

News

Sanofi pays $180m for rights to Kali autoimmune drug

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

News

Quell takes new Treg into clinic after transplant study halt

Quell Therapeutics changes tack, starting trials of a CAR-Treg in rheumatoid arthritis and systemic sclerosis and parking its transplant therapy.

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

X-ray of the hand in rheumatoid arthritis

Istesso backer sees silver lining in failed arthritis trial

Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.

News

Apple devices enrich patent data in arthritis trial

It can be challenging to follow the course of rheumatoid arthritis accurately in clinical assessments and trials due to “subtle and unpredictable” changes in symptoms – bu

News

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita

Sanofi pays $180m for rights to Kali autoimmune drug

Quell takes new Treg into clinic after transplant study halt

MSD advances on a broad front with TL1A drug tulisokibart

Istesso backer sees silver lining in failed arthritis trial

Apple devices enrich patent data in arthritis trial

Alfasigma to buy Galapagos’ JAK drug for up to €170m

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

Rheumatoid arthritis

Editor's Picks